{"transactions":[{"id":725475,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:18.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001952533-26-000002","document":"form4-06262026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195253326000002/form4-06262026_040612.xml","form_type":"4"}},{"id":1100216,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:19.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018388","document":"form4-06272025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018388/form4-06272025_040614.xml","form_type":"4"}},{"id":1470698,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-24T21:00:12.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 20, 2025 or the date of the Issuer's 2025 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":7.73,"expiration_date":"2034-06-19","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001415889-24-018012","document":"form4-06242024_050607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924018012/form4-06242024_050607.xml","form_type":"4"}},{"id":1842708,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T01:00:49.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 27, 2024 or the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":40000,"derivative":{"exercise_price":6.5,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-040113","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123040113/doc4.xml","form_type":"4"}},{"id":2120032,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2022-11-10T23:00:20.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":118190,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in exchange for a stock option to acquire 100,000 shares of common stock of ARS pursuant to the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares vest in a series of thirty-six (36) successive equal monthly installments measured from the vesting commencement date."}],"balance_after":118190,"derivative":{"exercise_price":1.44,"expiration_date":"2031-12-13","underlying":"Common Stock","underlying_shares":118190},"source":{"system":"sec-edgar","filing":"0001209191-22-056440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056440/doc4.xml","form_type":"4"}},{"id":2120031,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-11-10T23:00:20.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":70422,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for a stock option to acquire 59,584 shares of common stock of ARS pursuant to the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured the first anniversary of the vesting commencement date."}],"balance_after":70422,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":70422},"source":{"system":"sec-edgar","filing":"0001209191-22-056440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056440/doc4.xml","form_type":"4"}},{"id":2120030,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-10T23:00:20.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":83225,"ownership":{"direct":false,"nature":"The 2019 Michael Kelly Irrevocable Deed of Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 70,416 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock.  Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person's spouse and sister are trustees of the trust. The beneficiary of the trust is the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these Securities for purposes of Section 16 or for any other purpose."}],"balance_after":83225,"source":{"system":"sec-edgar","filing":"0001209191-22-056440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056440/doc4.xml","form_type":"4"}}]}